Article

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events

2025-01-08

Abstract excerpt

<h4>Background</h4> Dupilumab has been added to National Cancer Comprehensive Network (NCCN) guidelines as a therapeutic strategy for managing certain cutaneous immune-related adverse events (cirAEs) from immune checkpoint inhibitor (ICI) therapy. However, little is known about the implications of dupilumab for cancer outcomes in this population. In this multi-institutional study, we evaluate the impact of dupilum...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ff4708f-f4f8-5466-a7da-020c810aa28e
DOI: 10.1101/2025.01.07.25320156

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse eventsDOI 10.1101/2025.01.07.25320156Read

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity Read

Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort StudySemantic proximity Read

Biologic Treatment for Cutaneous Immune-Related Adverse Events in Cancer Patients Undergoing Immune-Checkpoint Therapy: A Retrospective ReviewSemantic proximity Read

The Oncology: Disease Modifying Anti-Rheumatic Drug Interface: A Cross-Specialty ReviewSemantic proximity Read

Prediction and treatment of skin adverse reactions related to inhibitors at immune checkpointsSemantic proximity Read

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsSemantic proximity Read

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read

Literature analysis of Cadonilimab-induced adverse drug reactionSemantic proximity Read

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsSemantic proximity Read

A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA’s adverse events reporting systemSemantic proximity Read